# SHR-1701 in Metastatic or Locally Advanced Solid Tumors

> **NCT03710265** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 206 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SHR-1701

## Key facts

- **NCT ID:** NCT03710265
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710265, "SHR-1701 in Metastatic or Locally Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03710265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*